Novel 3' end caps, 5' end caps and combinations thereof for therapeutic rna

Abstract

The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

1 . A compound of Formula I or a pharmaceutically acceptable salt thereof 
       
         
           
           
               
               
           
         
       
       wherein
 Z 1  is: 
 
       
         
           
           
               
               
           
         
         Z 2  is absent or a linking moiety selected from the group consisting of —O—, —S—, lower alkyl, aminoalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, 
       
       
         
           
           
               
               
           
         
         A 1  and A 3  are independently selected from the group consisting of absent, NH, S, and O; 
         A 2  is absent or selected from the group consisting of >CR 6 R 7 , >NR 6 , >NNR 6 R 7 , >NOR 6 , >S, and >O; 
         Y is absent or a linking moiety selected from the group consisting of lower alkyl, alkenyl, alkynyl, —(CH 2 ) n OR 15 , —(CH 2 ) n COOR 15 , and —(CH 2 ) n C(O)NR 12 ; 
         R 1  is selected from the group consisting of H, substituted cycloalkyl, substituted cycloalkenyl, substituted aryl, substituted heteroaryl, and substituted heterocyclyl; 
         R 5 , R 6 , and R 8  are independently selected from the group consisting of H, substituted alkyl, polyamine, PEGs, —(CH 2 ) n1 NR 12 R 13 , —(CH 2 ) n1 NR 14 C(O)R 15 , —(CH 2 ) n1 OR 15 , —(CH 2 ) n1 C(O)OR 15 , —(CH 2 ) n1 C(O)R 15 , —(CH 2 ) n1 C(O)NR 12 R 13 , —O—(CH 2 ) n3 —C(O)—(NR 12 ) 2 —C(O)—X 2 , —O—(CH 2 ) n3 —C(O)—[NR 12 —C(O)—(CH 2 ) n3 ] 1-3 —X 2 , or R 6  and R 8  together form a ring that is substituted and contains 10-80 ring atoms in which 10-40 ring atoms can be hetero atoms, or R 6  and R 7  together form a 3-8 membered ring that is substituted and in which 1 to 6 ring atoms can be hetero atoms; 
         R 7 , R 12 , R 13 , R 14 , R 15  and R 16  are independently selected from the group consisting of H, substituted lower alkyl, and substituted acyl; 
         R 9  is selected from the group consisting of H and substituted lower alkyl; 
         R 10  is selected from the group consisting of H, —NR 12 R 13 , and —OR 16 ; 
         n is 1 to 4; 
         n1 is zero to 10; 
         n2 is 1 to 12; 
         n3 is 1 to 8; 
         X is selected from the group consisting of O, S, NH, and substituted alkanediyl; 
         X 2  is selected from the group consisting of affinity moiety and detection moiety, and 
         X n  is a nucleobase. 
       
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . The compound of  claim 1 , which has the following formula 
       
         
           
           
               
               
           
         
       
       wherein
 A 2  is absent; and 
 the other variables are as defined in Formula I. 
 
     
     
         5 - 9 . (canceled) 
     
     
         10 . The compound of  claim 1 , which has the following formula 
       
         
           
           
               
               
           
         
       
       wherein
 -A 1 -R 5  and -A 3 -R 8  are —OH; 
 A 2  is absent; 
 X n  is a nucleobase, and 
 the other variables are as defined in Formula I. 
 
     
     
         11 - 14 . (canceled) 
     
     
         15 . A compound of Formula XI or a pharmaceutically acceptable salt thereof 
       
         
           
           
               
               
           
         
       
       wherein
 Z 2  is absent or a linking moiety selected from the group consisting of —O—, —S—, lower alkyl, aminoalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, 
 
       
         
           
           
               
               
           
         
         Y is absent or a linking moiety selected from the group consisting of lower alkyl, alkenyl, alkynyl, —(CH 2 ) n OR 15 , —(CH 2 ) n COOR 15 , and —(CH 2 ) n C(O)NR 12 ; 
         R 1  is selected from the group consisting of H, substituted cycloalkyl, substituted cycloalkenyl, substituted aryl, substituted heteroaryl, and substituted heterocyclyl; 
         R 9  is selected from the group consisting of H and substituted lower alkyl; 
         R 10  is selected from the group consisting of H, —NR 12 R 13 , and —OR 16 ; 
         R 12 , R 13 , R 15 , and R 16  are independently selected from the group consisting of H, substituted lower alkyl, and substituted acyl; 
         X is selected from the group consisting of O, S, NH, and substituted alkanediyl; 
         Z is selected from the group consisting of —OH, 
       
       
         
           
           
               
               
           
         
         n is 1 to 4; 
         n2 is 1 to 12; and 
         n4 is 0-2. 
       
     
     
         16 . The compound of  claim 15 , comprising a structure selected from the group consisting of: